Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA

EQS-News: aap Implantate AG / Key word(s): Half Year Results Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA 14.08.2024 / 19:15 CET/CEST The issuer is solely responsible for the content of this announcement. Sales: H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023; main growth driver EMEA region EBITDA: H1/2024 breaks even, Trauma achieves positive EBITDA aap Implantate AG ("aap" or "Company") looks back on a pleasing first half-year. The Company was able to increase sales and EBITDA compared to the previous year and generate a positive EBITDA in the trauma business. The company's sales increased by 10% to EUR 6.4 million compared to the same period of the previous year (H1/2023: EUR 5.9 million). In terms of earnings, the company recorded an almost balanced EBITDA of EUR ‑0.0 million (H1/2023: EUR -1.0 million) in the first six months of 2024, which primarily reflects the growth in sales coupled with lower costs and effects from restructuring.

H1/2024 - Key financial figures*

 

Turnover in TEUR	Q2/2024	Q2/2023	Change
EMEA (= Europe, Middle East, Africa) North America LATAM (= Latin America) APAC (= Asia-Pacific)	1.907 683 639 102	1.328 937 564 80	+44 % -27% +13 % +27 %
Turnover	3.330	2.909	+14 %
Turnover in TEUR	H1/2024	H1/2023	Change
EMEA (= Europe, Middle East, Africa)